Arcutis Biotherapeutics (ARQT) director sells 7,144 shares under 10b5-1 plan

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Howard G. Welgus sold shares of company stock in a planned transaction. On May 1, 2026, he completed an open-market sale of 7,144 shares of Arcutis common stock at a weighted average price of $22.9871 per share.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, which is scheduled to run through May 29, 2026. Following this transaction, Welgus directly holds 32,600 Arcutis common shares.

Insider Trade Summary 10b5-1

Net Seller: 7,144 shares ($164,220)

Net Sell 1 txn

Insider Welgus Howard G.

Role null

Sold 7,144 shs ($164K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,144	$22.9871	$164K

Holdings After Transaction: Common Stock — 32,600 shares (Direct, null)

Footnotes (1)

1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.79 to $23.25, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 7,144 shares Average sale price: $22.9871 per share Post-transaction holdings: 32,600 shares +2 more

5 metrics

Shares sold 7,144 shares Open-market sale of Arcutis common stock on May 1, 2026

Average sale price $22.9871 per share Weighted average sale price across multiple trades

Post-transaction holdings 32,600 shares Shares directly owned by Howard G. Welgus after the sale

10b5-1 plan adoption date March 11, 2025 Date Welgus adopted the Rule 10b5-1 trading plan

10b5-1 plan end date May 29, 2026 Scheduled end date of the trading plan governing the sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		S(1)		7,144	D	$22.9871(2)	32,600	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.79 to $23.25, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Arcutis Biotherapeutics (ARQT) report for Howard G. Welgus?

Arcutis Biotherapeutics reported that director Howard G. Welgus sold 7,144 shares of common stock in an open-market transaction on May 1, 2026. The trade was disclosed on a Form 4 insider filing with detailed pricing information and remaining holdings.

How many Arcutis (ARQT) shares did Howard G. Welgus sell and at what price?

Howard G. Welgus sold 7,144 shares of Arcutis common stock at a weighted average price of $22.9871 per share. The shares were sold in multiple trades within a price range from $22.79 to $23.25, according to the Form 4 footnote.

How many Arcutis Biotherapeutics (ARQT) shares does Howard G. Welgus own after the sale?

After the reported sale, Howard G. Welgus directly holds 32,600 shares of Arcutis common stock. This post-transaction ownership figure comes from the Form 4 filing’s disclosure of total shares beneficially owned following the transaction.

Was the Arcutis (ARQT) insider sale by Howard G. Welgus under a Rule 10b5-1 plan?

Yes. The Form 4 states the sale was executed under a Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026. Such plans pre-schedule trades to help manage insider trading concerns.

What does the weighted average sale price mean in the Arcutis (ARQT) Form 4 filing?

The weighted average sale price of $22.9871 per share reflects multiple trades executed between $22.79 and $23.25. The Form 4 notes that detailed trade-by-trade pricing can be provided to regulators, the issuer, or shareholders upon request.